NEW YORK (GenomeWeb News) – Investment bank Cantor Fitzgerald today initiated coverage of Cancer Genetics with a Buy rating and a $21 price target on its shares.

In a research note, analyst Sung Ji Nam said that challenges await companies developing and commercializing genomic tests, but Rutherford, NJ-based Cancer Genetics has strengths in leveraging clinical development collaborations with leading healthcare partners. Additionally, Nam said, the company has one of the most comprehensive sets of diagnostic services targeting cancer types.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.